Executive Summary
EpiStem Holdings plc is a biotechnology company commercialising adult stem cells in the areas of oncology and gastrointestinal diseases as well as cosmeceutical applications. The Company develops innovative therapeutics and diagnostic biomarkers and provides contract research services to drug development companies. The Company's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. EpiStem does not conduct research in the areas of embryonic stem cells or stem cell transplantation. EpiStem operates two distinct business divisions, Contract Research Services and Novel Therapies. Contract Research Services: Contract Research Services provides specialised preclinical efficacy testing primarily for drug development companies on a fee for service basis. This division on a standalone basis is cash generative and profitable, with an established five-year track record of providing testing services to over 65 company clients primarily in Europe and the United States. Novel Therapies: Novel Therapies is focused on developing its own innovative therapeutics and diagnostic biomarkers. Through its discovery platform. Novel Therapies has identified 250 potential drug candidates, of which a subset will undergo further evaluation as stem cell regulators for the Company's emerging drug development pipeline. Novel Therapies is also conducting feasibility studies with two drug development companies using its clinical diagnostic biomarker technology. The group employees 29 staff in total all of which are based at the Company's registered office.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
